The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18218 ↗At a glance
Kohortenstudie in Alimentary Pharmacology & Therapeutics, 2024. Written by Fangyuan Jiang and 6 co-authors. Institution: Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Glycation End Products, Advanced, Diet. Cited 11 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Key Research and Development Program of China, Key-Area Research and Development Program of Guangdong Province.
Abstract (original language)
Background
Dietary advanced glycation end products (AGEs) may promote oxidative stress and inflammation in the gastrointestinal tract.
Aims
The aim of this study is to investigate the association between dietary AGE intake and the risk of inflammatory bowel disease (IBD).
Methods
We included 121,978 participants without IBD at baseline from the UK Biobank. We estimated consumption of three common AGEs (Nε‐(carboxymethyl)‐lysine (CML), Nε‐(1‐carboxyethyl)‐lysine (CEL), and Nδ‐(5‐hydro‐5‐methyl‐4‐imidazolon‐2‐yl)‐ornithine (MG‐H1)) by matching 24‐h dietary questionnaires to a validated dietary AGE database. We used Cox proportional hazards regression models to calculate the hazard ratio (HR) and 95% CI of the association between dietary AGEs and IBD risk.
Results
During a median follow‐up of 13.72 years, 671 participants developed IBD (192 with Crohn's disease (CD) and 478 with ulcerative colitis (UC)). Among the assessed dietary AGEs, only CEL was associated with an increased risk of IBD (HR = 1.09, 95% CI: 1.01–1.18, p = 0.020) and CD (HR = 1.18, 95% CI: 1.03–1.36, p = 0.014), particularly for participants who were overweight, physically inactive, and non‐smokers. Among participants at a high genetic risk of CD, HRs (95% CI) of CD were 1.26 (1.00–1.57) for CML, 1.41 (1.12–1.77) for CEL, and 1.28 (1.01–1.62) for MG‐H1 ( p < 0.05 for each). However, none of the dietary AGEs was significantly associated with UC risk, irrespective of genetic predisposition.
Conclusions
Dietary CEL was associated with an increased risk of IBD and CD, but not UC. Further interventional studies are required to support the potential benefit of AGE restriction, especially for individuals at a high genetic risk of CD.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Big Data in Health Science, The Second Affiliated Hospital and School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
- Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Institute of Gastroenterology, Zhejiang University, Hangzhou, China.
ORCID profiles: Fangyuan Jiang, Qian Cao
Funding
- National Key Research and Development Program of China
- Key-Area Research and Development Program of Guangdong Province
Cite
APA
Jiang, F., Yang, W., Cao, Y., Cao, X., Zhang, Y., Yao, L., & Cao, Q. (2024). The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18218
Vancouver
Jiang F, Yang W, Cao Y, Cao X, Zhang Y, Yao L, et al. The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18218
BibTeX
@article{Jiang2024,
author = {Jiang, Fangyuan and Yang, Wenjing and Cao, Yushu and Cao, Xianghan and Zhang, Yu and Yao, Lingya and Cao, Qian},
title = {The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18218}
}
EUVIMED